微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 41.5% | -15.55% | -15.95% | 91/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 49.37% | 2.57% | -1.04% | 79/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 49.89% | 6.06% | -2.12% | 80/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 50.97% | 5.82% | 3.73% | 78/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 49.14% | 3.14% | 2.09% | 81/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 48.14% | -9.77% | 2.33% | 82/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 47.04% | -6.95% | -2.34% | 88/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 48.17% | -4.73% | 1.1% | 85/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 47.65% | -4.75% | -10.69% | 83/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 53.35% | -2.35% | 5.53% | 78/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 50.55% | -1.7% | -0.02% | 79/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 50.56% | -4.16% | 1.08% | 85/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 50.02% | -4.05% | -8.44% | 80/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 54.63% | 1.47% | 6.23% | 79/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 51.43% | -3.94% | -2.52% | 71/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 52.76% | 4.69% | 1.2% | 75/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 52.13% | 8.97% | -3.17% | 69/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 53.84% | -10.55% | 0.56% | 76/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 53.54% | -14.04% | 6.24% | 65/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 50.39% | -24.2% | 5.34% | 71/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 47.84% | -28.03% | -20.52% | 69/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 60.19% | -12.26% | -3.36% | 59/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 62.28% | -5.99% | -6.31% | 42/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 66.48% | 2.79% | 0.01% | 35/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 66.47% | 7.5% | -3.09% | 27/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 68.6% | -0.47% | 3.55% | 39/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 66.25% | -0.28% | 2.43% | 26/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 64.68% | 0.59% | 4.59% | 32/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 61.84% | -3.25% | -10.27% | 36/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 68.92% | 17.83% | 3.74% | 29/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 66.44% | 20.12% | 3.33% | 23/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 64.3% | 21.49% | 0.59% | 23/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 63.92% | 20.57% | 9.28% | 23/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 58.49% | 2.71% | 5.75% | 35/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 55.31% | 2.42% | 4.5% | 25/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 52.92% | -2.33% | -0.17% | 32/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 53.01% | 1.85% | -6.91% | 23/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 56.95% | 9.47% | 5.46% | 30/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 54% | 9.65% | -0.34% | 22/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 54.19% | 11.97% | 4.11% | 27/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 52.05% | 6.91% | 0.05% | 27/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |